Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Cardiologist shares positive first-in-human data on TriCares TTVR device
The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.
No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving
Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.
CMS proposes Medicare coverage for T-TEER
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
First comprehensive T-TEER resource examines best practices for tricuspid valve repair
"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.
Key trends in transcatheter tricuspid valve interventions
Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

FDA panel to consider Abbott’s TriClip device for tricuspid regurgitation

The panel's decision will be based on data from the TRILUMINATE study, which was ultimately positive for Abbott, but did lead to certain questions about patient outcomes.

FDA approves first transcatheter tricuspid valve replacement device, the EVOQUE system from Edwards Lifesciences

Edwards makes history, receives FDA approval for transcatheter tricuspid valve replacement device

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board

The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation.

Video of Kendra Grubb discussing transcatheter tricuspid and mitral advancements at TCT 2023.

Key trends in transcatheter tricuspid and mitral valve technologies

The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023.

The Evoque transcatheter tricuspid valve replacement (TTVR) system for tricuspid regurgitation from Edwards Lifesciences

More good news for Edwards: ‘Landmark study’ confirms new TTVR system reduces tricuspid regurgitation, improves symptoms

New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR.

Edwards Lifesciences gains CE mark approval for Evoque transcatheter tricuspid valve replacement (TTVR) system

Edwards gains CE mark approval for new tricuspid valve replacement device

The approval represents a significant moment in the treatment of structural heart disease. Edwards will share updated data on the device at TCT 2023 in San Francisco.

Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.

What new tricuspid valve data tell us about the future of patient care

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out.

K-Clip Transvascular Tricuspid Repair System from Huihe Healthcare

Cardiologists use new annular clipping device for first time in US to treat severe tricuspid regurgitation

Interventional cardiologists with Henry Ford Health performed the historic procedure on an 85-year-old patient who had been experiencing worsening symptoms for a full year.

Tricuspid Valve

Cardiologist shares positive first-in-human data on TriCares TTVR device

No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving

CMS proposes Medicare coverage for T-TEER

First comprehensive T-TEER resource examines best practices for tricuspid valve repair

Key trends in transcatheter tricuspid valve interventions